Chafic Karam, MD

Neurology
Accepting new patients
Sees patients age 18 and up
Penn Neuroscience Center - Neurology
Schedule onlineCall 800-789-7366
Headshot of Chafic Karam, MD
Penn Medicine Provider

About me

  • Chief, Neuromuscular Division
  • Professor of Clinical Neurology

My education and training

  • Medical School: Saint Joseph's University
  • Residency: Hotel Dieu de France
  • Residency: Mount Sinai Hospital
  • Residency: Mass General Brigham Healthcare Center - Chestnut Hill
  • Residency: Mayo Clinic

Spoken languages

English
English

Reviews

Average Rating

218 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
June 2026
dr. karam takes the time to answers my many questions. he is a very knowledgeable physician.
Anonymous
May 2026
dr karam is an expert at what he does and what i like the best about him is he gave me as much time as i needed to have all of my questions answered. he extended my exam to make sure that he left no stone unturned with my neurological condition. he is a kind and very intelligent doctor. i feel extremely safe with him and blessed that i have a neurologist of his capacity.
Anonymous
May 2026
seems very sincere
Anonymous
May 2026
expert in his field and great bedside manner

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Karam is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Allen JA, Eftimov F, Querol L, Sommer C, Dimachkie MM, Fix C, Gable K, Gorson KC, Harbo T, Karam C, Koike H, Kuitwaard K, Lunn MP, Nobile-Orazio E, Pasnoor M, Rajabally YA, Peric S, Reisin R, Butler L; Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy , Neurology: 2026 Jul 14;107(1):e218159.

Dvorak JE, Khella S, Drachman B, Row R, Pieretti J, Mathelier H, Karam C. Polyneuropathy in p.V142I hereditary transthyretin amyloidosis: Diagnostic challenges and clinical considerations , J Neurol Sci. : 2026

Donofrio PD, Gorson KC, Hofman E, Karam C, Kira JI, Kostera-Pruszczyk A, Léger JM, Nobile-Orazio E, Attarian S, Markov M, Tse A, De Roeck A, Lewis RA. Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20 , J Neurol Sci. : 2026

John E. Dvorak, Sami Khella, Brian Drachman, Rebecca Row, Janice Pieretti, Hansie Mathelier, Chafic Karam Prevalence and attribution of polyneuropathy in p.V142I (V122I) hereditary transthyretin amyloidosis , Journal of the Neurological Sciences: 2026

Joban Vaishnav, Dimitrios Bampatsias, Brian C. Boursiquot, Yevgeniy Brailovsky, Kristin Hsu, Jamie Zigterman, Rajshekhar Chakraborty, Ashutosh Wechalekar, Pablo Garcia Pavia, Ronald Witteles, Mazen Hanna, Chafic Karam, Mathew S. Maurer, and Jan M. Griffin Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art Review , JACC: CardioOncology , 8(2): 2026

Karam C. Clinical Utility of Serum Neurofilament Light Chain in Peripheral Neuropathy. , Muscle Nerve. : 2026,73(1):86-92.

Chakraborty R, Brailovsky Y, Hanna M, Witteles R, Vaishnav J, Hoffman JE, Griffin JM, Garcia-Pavia P, Wolinsky D, Karam C, Lachmann HJ, Gertz MA, Boursiquot BC, Bampatsias D, Hsu K, Johnson PT, Zigterman JL, Kazemzadeh AC, Maurer MS, Wechalekar AD. Prognostic Factors and Progression Biomarkers in AL Amyloidosis: Mapping Current Knowledge and Critical Gaps , Blood. 2026 Mar 4:blood.2025031651.: 2026

Fedak RR, Ruggerie RN, Shan Y, Curvino EJ, de Sousa JF, Daniel S, Ngo-Casi M, Kamboh H, Vu T, Durmuş H, Mozaffar T, Howard JF Jr, English EP, Benson A, Duvernay MT, Singer MS, Kalayoglu MV, Brunn C, Bodansky A, Anderson MS, DeRisi JL, Garcia ST, Yu DJL, Zorn KC, Kurtoglu M, Miljković MD, Stewart CA, Jewell CM; MG-001 Study Team. BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial , Nat Med: 2026

Vu T, Durmus H, Rivner M, Shroff S, Ragole T, Myers B, Pasnoor M, Small G, Karam C, Vullaganti M, Peltier A, Sahagian G, Feinberg MH, Slanksy A, Barnett-Tapia C, Siddiqi Z, Gwathmey K, Badruddoja MA, Kamboh H, Ruggerie RN, Fedak RR, Stewart CA, Kurtoglu M, Kalayoglu M, Singer M, Jewell CM, Miljkovic MD, Dimachkie M, Mozaffar T, Howard JF Jr; MG-001 Study Team. BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial , Nat Med. : 2026

Blein C, Karam C, Arvin-Berod C, Gelinas D, Barrera-Sierra S, Syed HUTA, Ward C, Goyal A, Guptill J. Real-world treatment utilization in adults with chronic inflammatory demyelinating polyneuropathy in the United States. , Front Neurol. 2026 Jan 29;16:1726857: 2026

View all publications